tumor necrosis factor alpha-induced protein 3

肿瘤坏死因子 α 诱导蛋白 3
  • 文章类型: Systematic Review
    A20单倍体功能不全(HA20)是一种由NF-κB通路缺陷失活引起的自身炎症性疾病。我们对2016年至2023年8月遵循PRISMA指南的TNFAIP3突变患者报告文章进行了系统的文献综述。检索了来自65篇文章的177名患者(108名女性)的数据。主要特征是:粘膜溃疡(n=129),发烧(n=93),其次是胃肠道(n=81),皮肤特征(n=76),自身免疫(n=61),包括甲状腺炎(n=25)和狼疮(n=16),和关节参与(n=54)。截至发稿时,已有5名患者死亡。在54/63患者中,C反应蛋白在耀斑期间显着升高,中位数为51mg/L。最常用的治疗包括皮质类固醇和非甾体抗炎药(n=32),TNF-阻断剂(n=29),秋水仙碱(n=28)和甲氨蝶呤(n=14)。TNFAIP3变异体影响92例OTU结构域和68例锌指结构域。地理起源,性别和变异类型显著影响表型。更好地了解广泛的HA20表型可以促进诊断过程。关于HA20患者的发病机制和治疗以改善结果仍有许多有待阐明。
    A20 haploinsufficiency is an autoinflammatory disease caused by defective inactivation of the NF-κB pathway. We conducted a systematic literature review of articles reporting patients with TNFAIP3 sequence variants from 2016 to August 2023 following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Data from 177 patients from 65 articles were retrieved (108 women). The principal features were mucosal ulcers (n = 129); fever (n = 93) followed by gastrointestinal (n = 81); skin features (n = 76); autoimmunity (n = 61), including thyroiditis (n = 25) and lupus (n = 16); and joint involvements (n = 54). Five patients had died at the time of publication. In 54 of 63 patients, CRP was significantly elevated during flares, with a median of 51 mg/l. The most commonly used treatment included corticosteroids and nonsteroidal anti-inflammatory drugs (n = 32), TNF blockers (n = 29), colchicine (n = 28), and methotrexate (n = 14). TNFAIP3 variants impacted the ovarian tumor domain in 92 cases and a Zinc finger domain in 68 cases. Geographic origin, reported sex, and variant type significantly impacted phenotype. A better understanding of the wide A20 haploinsufficiency phenotype could facilitate the diagnosis process. Much remains to be elucidated about pathogenesis and treatment to improve outcome in patients with A20 haploinsufficiency.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Objective: To summarize the clinical characteristics of patients with haploinsufficiency of A20 (HA20). Methods: The clinical manifestations, laboratory examinations, treatment, outcome and genetic analysis of 4 cases with HA20 hospitalized in Peking Union Medical College Hospital were analysed.Further literature review was done after searching articles in PubMed and Wangfang databases with the key words \"HA20\" \"A20 haploinsufficiency\" \"TNFAIP3\" up to the date of September 2019. Results: The 4 patients were a father and a daughter, as well as a mother and a daughter. Their phenotypes were quite variable, but all of them have been suffering from recurrent oral ulcer since childhood. Elevation of C-reactive protein (13-33 mg/L) and erythrocyte sedimentation rate (21-60 mm/1h) were found in these 4 patients, and there was positive antinuclear antibody in proband 1.The father in pedigree 1 and the 2 patients in pedigrees 2 have been diagnosed with Behçet disease and the proband 1 with undifferentiated connective tissue disease. The 2 patients in pedigree 1 have developed Hashimoto\'s thyroiditis. After gene sequencing analysis, it was found that all the 4 patients have heterozygous nonsense mutations in TNFAIP3 gene, that is, c.811C>T, p.R271X in pedigree 1 and c.133C>T, p.R45X in pedigree 2.The diagnosis of HA20 was eventually established when sequencing results and their clinical manifestations were both compatible with this disease.A total of 21 articles were retrieved, all in English, with a total of 91 cases from 39 families (including the 4 cases reported in this paper). HA20 was reported more often in female (57, 64.8%). Most patients develop symptoms from childhood, but as many as 53.4% (47 cases) are not correctly diagnosed until adulthood. Oral ulcers, genital ulcers, periodic fever, gastrointestinal symptoms, rashes, and arthritis are the primary manifestations.Hashimoto\'s thyroiditis is the most common autoimmune diseases that HA20 patients coexist with. Laboratory tests were characterized by significantly elevated inflammatory markers and low to moderate titers of autoantibodies in some patients.Most HA20 patients were reported to have nonsense mutations or shift mutations of TNFAIP3 gene, which leads to truncation of A20 protein, and only a small number of patients have missense mutation. In terms of treatment, anti-TNF treatment and anti-interleukin 1 is believed to be an effective and the most optimal therapy. The treatment effect is variable and requires long term observations. Conclusions: The clinical phenotypes of HA20 are complex. For patients with both autoinflammatory and autoimmune characteristics, family history should be inquired in detail and gene sequencing should be performed if necessary.
    目的: 总结A20单倍剂量不足(HA20)的临床特点。 方法: 报道北京协和医院收治的2家系4例HA20患者的临床表现、治疗、转归和基因测序结果。并以\"A20单倍剂量不足\" \"HA20\" \"TNFAIP3\"为关键词,检索截至2019年9月万方数据库和PubMed数据库的文献进行复习。 结果: 4例患者系一对父女及一对母女,临床表现差异较大,但4例患者自幼均有反复口腔溃疡,均有C反应蛋白(13~33 mg/L)、红细胞沉降率(21~60 mm/1h)升高,先证者1还有抗核抗体阳性。先证者1的父亲和先证者2及其母亲曾被诊断为白塞病,先证者1被诊断为未分化结缔组织病。家系1的父女均合并桥本甲状腺炎。基因测序示4例患者均存在TNFAIP3基因杂合的无义突变:家系1为c.811C>T,p.R271X杂合突变,家系2为c.133C>T,p.R45X杂合突变。结合临床表现修正诊断为HA20。检索到的HA20病例报道共21篇,均为英文报道,共计39个家系、91例患者(包括本组4例)。患者以女性居多(57例,64.8%),多于儿童时期起病,但多达53.4%(47例)的患者至成年期才被确诊。口腔和(或)生殖器溃疡、周期热、消化道症状、皮疹和关节炎是最常见的临床表现,可合并多种自身免疫性疾病,其中以桥本甲状腺炎最为常见。实验室检查特点为炎症指标明显升高,部分患者存在低至中等滴度的自身抗体。大部分HA20患者存在TNFAIP3基因无义突变或移码突变,导致A20蛋白截短,少部分患者存在错义突变,而干扰其对核因子κB通路的抑制。治疗上,HA20患者可选用白细胞介素1拮抗剂或肿瘤坏死因子拮抗剂治疗,远期预后个体差异大,严重者有死亡风险。 结论: HA20临床表现复杂,对兼有自身炎症和自身免疫特点的患者,应详细询问家族史,必要时完善基因测序,以帮助患者确诊及产前诊断。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    BACKGROUND: Behçet disease (BD) is a systemic vasculitis involving vessels from any size with various clinical features. Most BD cases are multifactorial and associated with the HLA B51 antigen. In rare and severe early onset cases, dominant Mendelian transmission has been linked to mutations in the TNFAIP3 gene encoding A20. Herein, we propose a systematic review of the literature about the haploinsufficiency A20 (HA20) published cases.
    UNASSIGNED: Our review of the 45 cases of HA20 from literature highlights the similarities and the differences between this genetic auto-inflammatory disease and classical BD. HA20 looks like BD if we consider recurrent oral (87%) and genital (67%) ulcers, arthralgia or arthritis (42%), skin involvement (53%) such as erythema nodosum or abdominal symptoms (60%) such as abdominal pain, digestive ulcers or diarrhea. However, HA20 differs from classical BD because its geographical distribution is ubiquitous, sex ratio is inversed (one man for two women), first symptoms occur in early childhood (median age = 5.5 years; interquartile range: 1-10) instead of adulthood, recurrent fever is common (62%) unlike classical BD, HLA B51 antigen is uncommon and abdominal symptoms are over-represented compared to classical BD. In addition, response to colchicine in HA20 is inconstant (24%) unlike classical BD.
    CONCLUSIONS: High fever flares and digestive involvement starting in early childhood seem to be hallmarks of HA20 clinical features. Response to colchicine is unpredictable and biotherapies like anti-TNFα and anti IL1 appear to be treatments of choice, like for other auto-inflammatory diseases. Prospective description of larger cohort of HA20 cases is needed to understand better when this disease must be looked for and how to treat these patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Rheumatoid arthritis (RA) is one of the most common autoimmune diseases. As with other complex traits, genome-wide association studies (GWASs) have tremendously enhanced our understanding of the complex etiology of RA. In this review, we describe the genetic architecture of RA as determined through GWASs and meta-analyses. In addition, we discuss the pathologic mechanism of the disease by examining the combined findings of genetic and functional studies of individual RA-associated genes, including HLA-DRB1, PADI4, PTPN22, TNFAIP3, STAT4, and CCR6. Moreover, we briefly examine the potential use of genetic data in clinical practice in RA treatment, which represents a challenge in medical genetics in the post-GWAS era.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号